Massachusetts General Hospital ( Site 4003)

Boston, Massachusetts 02114

0 studies enrolling now · 1 studies all time

What they study most

Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease

Studies at this site

• Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) — Running, not enrolling